Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score (CFRSD-CRISS)

• Published in: Journal of cystic fibrosis 2019-11, Vol.18 (6), p.886-893
• Main Authors: Gold, Laura S., Patrick, Donald L., Hansen, Ryan N., Goss, Christopher H., Kessler, Larry
• Format: Article
• Language: English
• Subjects: Adult; Bias; Correlation of Data; Cystic fibrosis; Cystic Fibrosis - diagnosis; Cystic Fibrosis - physiopathology; Cystic Fibrosis - psychology; Cystic Fibrosis - therapy; Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score; Diagnostic Self Evaluation; Female; Humans; Lung function; Male; Medical Records - standards; Medical Records - statistics & numerical data; Patient Reported Outcome Measures; Pulmonary exacerbations; Quality of Life; Respiratory Function Tests - methods; Respiratory Function Tests - statistics & numerical data; Surveys and Questionnaires; Symptom Assessment - methods; Symptom Assessment - psychology; Symptom Assessment - statistics & numerical data
• ISSN: 1569-1993; 1873-5010
• DOI: 10.1016/j.jcf.2019.05.009

Pulmonary exacerbations (PEx) in cystic fibrosis (CF) patients reduce quality of life. Lung function, measured by the percent predicted forced expiratory volume in 1 s (ppFEV1), is widely used to evaluate PEx treatments. We analyzed the correspondence of ppFEV1 with 8 patient-reported symptom-based questions from the Cystic Fibrosis Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). Data were derived from the observational Standardized Treatment of Pulmonary Exacerbations (STOP) study. CF patients who had CFRSD-CRISS and ppFEV1 measurements on ≥2 timepoints were included: 1) day of initial PEx, 2) 7 days later, and/or 3) end of PEx. We calculated age-stratified Spearman correlation coefficients and 95% confidence intervals (95% CIs) between the change in ppFEV1 and change in CFRSD-CRISS items from index to day 7 and from index to the end of PEx treatment. Lung function and symptom scores improved by the end of treatment; however, correlations between ppFEV1 and the specific CFRSD-CRISS measures were mostly weak to moderate. An exception was that among patients